Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings

Overview of attention for article published in Frontiers in oncology, April 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,556 followers.

New research: Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings: With the advent of tyrosine kinase inhibitors (TKIs), the… https://t.co/

16 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.